Bicara Therapeutics Inc. Common Stock (BCAX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Bicara Therapeutics Inc. ...

    NASDAQ: BCAX · Real-Time Price · USD
    12.06
    0.06 (0.50%)
    At close: Sep 04, 2025, 3:59 PM

    Bicara Therapeutics Common Stock Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022
    Revenue
    		 n/a n/a n/a
    Cost of Revenue
    		 56K 19K 10K
    Gross Profit
    		 -56K -19K -10K
    Operating Income
    		 -82.39M -39.89M -37.66M
    Interest Income
    		 14.58M 1.31M 4K
    Pretax Income
    		 -67.81M -51.98M -37.84M
    Net Income
    		 -68M -51.98M -37.84M
    Selling & General & Admin
    		 18.77M 9.27M 6.34M
    Research & Development
    		 8.22M 30.62M 31.31M
    Other Expenses
    		 55.4M n/a n/a
    Operating Expenses
    		 82.39M 39.89M 37.66M
    Interest Expense
    		 n/a n/a 112K
    Selling & Marketing Expenses
    		 n/a n/a n/a
    Cost & Expenses
    		 82.39M 39.89M 37.66M
    Income Tax Expense
    		 187K 5K 1K
    Shares Outstanding (Basic)
    		 54.42M 51.76M 51.76M
    Shares Outstanding (Diluted)
    		 54.42M 51.76M 51.76M
    EPS (Basic)
    		 -1.25 -1 -0.73
    EPS (Diluted)
    		 -1.25 -1 -0.73
    EBITDA
    		 -67.75M -51.96M -37.72M
    EBIT
    		 -67.81M -51.98M -37.73M
    Depreciation & Amortization
    		 56K 19K 10K

    Add to Watchlist